{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:39:02Z","timestamp":1787017142899,"version":"build-2736575974"},"reference-count":38,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,2,24]]},"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the impact of sustained low disease activity (LDA)\/remission (REM) on physical function, quality of life (QoL) and structural outcomes in secukinumab-treated psoriatic arthritis (PsA) patients from the FUTURE 5 study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FUTURE 5 was a randomised, double-blind, placebo-controlled, parallel-group, phase 3 study in patients with active PsA. Patients were categorised according to LDA (Minimal Disease Activity, MDA\/Disease Activity index for Psoriatic Arthritis, DAPSA LDA+REM) or REM (very LDA\/DAPSA REM): not achieving LDA\/REM, achieving it once or sustained LDA\/REM \u22653 times up to week 104. Key outcomes were improvements in Health Assessment Questionnaire Disability Index and Short Form-36 Physical Component Summary Score, proportion of non-radiographic progressors and predictors of sustained LDA response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients were randomised (N=996) into the following treatment groups: secukinumab 300\u2009mg (N=222), secukinumab 150\u2009mg loading (N=220)\/non-loading (N=222) and placebo (N=332). Baseline characteristics were comparable between patients with sustained DAPSA and MDA responses. By week 104, 48%\u201381% and 19%\u201336% of the secukinumab-treated patients achieved sustained LDA and REM, respectively. Numerically greater improvements in physical function and QoL were observed with sustained LDA\/REM versus LDA\/REM achieved once or not at all, although patients reached the established minimal clinically important difference for all composite indices. A high proportion of secukinumab-treated patients were non-structural progressors at 2 years irrespective of achieving sustained LDA\/REM. Younger age, lower body mass index at baseline, reduced tender joint count and PsA pain at week 16 were key predictors of sustained LDA in secukinumab-treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sustained LDA\/REM was associated with improvements in physical function, QoL and inhibition of structural damage progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002939","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T13:55:21Z","timestamp":1682344521000},"page":"e002939","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02404350","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"first","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Swedish Medical Centre\/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D","family":"Gladman","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Toronto Western Hospital, University of Toronto, Schroeder Arthritis Institute, Krembil Research Institute, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Navarra","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Santo Tomas Hospital, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Bao","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine","family":"Gaillez","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"issue":"Suppl 2","key":"2025090313504508000_9.2.e002939.1","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64 Suppl 2","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025090313504508000_9.2.e002939.2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0032-x"},{"key":"2025090313504508000_9.2.e002939.3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313504508000_9.2.e002939.4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.semarthrit.2020.03.015","article-title":"Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study","volume":"50","author":"Coates","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313504508000_9.2.e002939.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"},{"key":"2025090313504508000_9.2.e002939.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2025090313504508000_9.2.e002939.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2025090313504508000_9.2.e002939.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00347-5"},{"key":"2025090313504508000_9.2.e002939.9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/acr2.11097","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 future 1 study","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2025090313504508000_9.2.e002939.10","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/S2665-9913(20)30036-9","article-title":"Long-Term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 future 2 study","volume":"2","author":"McInnes","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"2025090313504508000_9.2.e002939.11","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (future 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090313504508000_9.2.e002939.12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and safety of subcutaneous secukinumab 150 Mg with or without loading regimen in psoriatic arthritis: results from the future 4 study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025090313504508000_9.2.e002939.13","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001600","article-title":"Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the future 5 study","volume":"7","author":"Mease","year":"2021","journal-title":"RMD Open"},{"key":"2025090313504508000_9.2.e002939.14","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/rheumatology\/kez420","article-title":"Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, future 5","volume":"59","author":"van der Heijde","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313504508000_9.2.e002939.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"2025090313504508000_9.2.e002939.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.20775"},{"key":"2025090313504508000_9.2.e002939.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"2025090313504508000_9.2.e002939.18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151290"},{"key":"2025090313504508000_9.2.e002939.19","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1007\/s10067-018-4227-7","article-title":"Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-psa randomized controlled trial","volume":"37","author":"Walsh","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025090313504508000_9.2.e002939.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209511"},{"key":"2025090313504508000_9.2.e002939.21","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.23537","article-title":"Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313504508000_9.2.e002939.22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/acr.22576","article-title":"Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study","volume":"68","author":"Kavanaugh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313504508000_9.2.e002939.23","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-2126-1","article-title":"Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial","volume":"22","author":"Mease","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025090313504508000_9.2.e002939.24","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000415","article-title":"Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial","volume":"3","author":"Mease","year":"2017","journal-title":"RMD Open"},{"key":"2025090313504508000_9.2.e002939.25","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.semarthrit.2020.01.012","article-title":"Remission in psoriatic arthritis: definition and predictors","volume":"50","author":"Alharbi","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313504508000_9.2.e002939.26","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/acr.20162","article-title":"Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313504508000_9.2.e002939.27","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2016.1220809"},{"key":"2025090313504508000_9.2.e002939.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2025090313504508000_9.2.e002939.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.2090"},{"key":"2025090313504508000_9.2.e002939.30","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/rheumatology\/key417","article-title":"Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity","volume":"58","author":"Landew\u00e9","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"#cr-split#-2025090313504508000_9.2.e002939.31.1","doi-asserted-by":"crossref","unstructured":"Smolen J , Aletaha D , Gladman D , et al . FRI0498\u2005Outcomes associated with achievement of various treatment targets in patients with psoriatic arthritis receiving adalimumab. Annual European Congress of Rheumatology, 14-17 June, 2017","DOI":"10.1136\/annrheumdis-2017-eular.3762"},{"key":"#cr-split#-2025090313504508000_9.2.e002939.31.2","doi-asserted-by":"crossref","unstructured":"June 2017:Suppl doi:10.1136\/annrheumdis-2017-eular.3762","DOI":"10.1136\/annrheumdis-2017-eular.3762"},{"key":"2025090313504508000_9.2.e002939.32","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.090019"},{"key":"2025090313504508000_9.2.e002939.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.22143"},{"key":"2025090313504508000_9.2.e002939.34","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0671-9","article-title":"Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the abatacept study to gauge remission and joint damage progression in methotrexate (MTX) -naive patients with early erosive rheumatoid arthritis (agree)","volume":"17","author":"Smolen","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025090313504508000_9.2.e002939.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200395"},{"key":"2025090313504508000_9.2.e002939.36","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000638","article-title":"Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the corrona psoriatic arthritis\/spondyloarthritis registry","volume":"4","author":"Mease","year":"2018","journal-title":"RMD Open"},{"key":"2025090313504508000_9.2.e002939.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204448"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:50:55Z","timestamp":1756932655000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,4,24]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1136\/rmdopen-2022-002939"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002939","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}